Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2022

Open Access 04-02-2022 | Primary Sclerosing Cholangitis | Review

TNF in the liver: targeting a central player in inflammation

Authors: Gisa Tiegs, Andrea K. Horst

Published in: Seminars in Immunopathology | Issue 4/2022

Login to get access

Abstract

Tumour necrosis factor-α (TNF) is a multifunctional cytokine. First recognized as an endogenous soluble factor that induces necrosis of solid tumours, TNF became increasingly important as pro-inflammatory cytokine being involved in the immunopathogenesis of several autoimmune diseases. In the liver, TNF induces numerous biological responses such as hepatocyte apoptosis and necroptosis, liver inflammation and regeneration, and autoimmunity, but also progression to hepatocellular carcinoma. Considering these multiple functions of TNF in the liver, we propose anti-TNF therapies that specifically target TNF signalling at the level of its specific receptors.
Literature
1.
DI Jang, AH Lee, HY Shin, HR Song, JH Park, TB Kang et al (2021) The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics. Int J Mol Sci 22(5)
2.
Brenner D, Blaser H, Mak TW (2015) Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol 15(6):362-3–74PubMedCrossRef
3.
Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE et al (2013) Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 11(5):558–64 e3PubMedCrossRef
4.
Bradham CA, Plumpe J, Manns MP, Brenner DA, Trautwein C (1998) Mechanisms of hepatic toxicity I TNF-induced liver injury. Am J Physiol 275(3):G387-92PubMed
5.
Wullaert A, van Loo G, Heyninck K, Beyaert R (2007) Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 28(4):365–386PubMedCrossRef
6.
Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N et al (2013) Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 58(3):529–534PubMedCrossRef
7.
Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108PubMedCrossRef
8.
Dostert C, Grusdat M, Letellier E, Brenner D (2019) The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev 99(1):115–160PubMedCrossRef
9.
Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376(6536):167–170PubMedCrossRef
10.
Yamada Y, Kirillova I, Peschon JJ, Fausto N (1997) Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A 94(4):1441–1446PubMedPubMedCentralCrossRef
11.
Yamada Y, Webber EM, Kirillova I, Peschon JJ, Fausto N (1998) Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology 28(4):959–970PubMedCrossRef
12.
Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745–756PubMedCrossRef
13.
Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ (1998) The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol 18(11):6353–6364PubMedPubMedCentralCrossRef
14.
Chen X, Oppenheim JJ (2011) Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. Int Immunopharmacol 11(10):1489–1496PubMedPubMedCentralCrossRef
15.
Salomon BL (2021) Insights into the biology and therapeutic implications of TNF and regulatory T cells. Nat Rev Rheumatol 17(8):487–504PubMedCrossRef
16.
EA Carswell, LJ Old, RL Kassel, S Green, N Fiore, B Williamson (1975) An endotoxin-induced serum factor that causes tumor necrosis. Proc Natl Acad Sci USA 72
17.
Lehmann V, Freudenberg MA, Galanos C (1987) Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med 165(3):657–663PubMedCrossRef
18.
Tiegs G, Wolter M, Wendel A (1989) Tumor necrosis factor is a terminal mediator in galactosamine endotoxin-induced hepatitis in mice. Biochem Pharmacol 38(4):627–631PubMedCrossRef
19.
Keppler DO, Pausch J, Decker K (1974) Selective uridine triphosphate deficiency induced by D-galactosamine in liver and reversed by pyrimidine nucleotide precursors. Effect on ribonucleic acid synthesis. J Biol Chem 249(1):211–6PubMedCrossRef
20.
Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G, Wendel A (1994) Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 153(4):1778–1788PubMed
21.
Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A et al (1993) Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock yet succumb to L monocytogenes infection. Cell 73(3):457–67PubMedCrossRef
22.
Leist M, Gantner F, Jilg S, Wendel A (1995) Activation of the 55-Kda Tnf receptor is necessary and sufficient for Tnf-induced liver-failure, hepatocyte apoptosis, and nitrite release. J Immunol 154(3):1307–1316PubMed
23.
Sass G, Shembade ND, Haimerl F, Lamoureux N, Hashemolhosseini S, Tannapfel A et al (2007) TNF pretreatment interferes with mitochondrial apoptosis in the mouse liver by A20-mediated down-regulation of Bax. J Immunol 179(10):7042–7049PubMedCrossRef
24.
Sass G, Shembade ND, Tiegs G (2005) Tumour necrosis factor alpha (TNF)-TNF receptor 1-inducible cytoprotective proteins in the mouse liver: relevance of suppressors of cytokine signalling. Biochem J 385(Pt 2):537–544PubMedPubMedCentralCrossRef
25.
Sieber S, Lange N, Kollmorgen G, Erhardt A, Quaas A, Gontarewicz A et al (2012) Sharpin contributes to TNFalpha dependent NFkappaB activation and anti-apoptotic signalling in hepatocytes. PLoS One 7(1):e29993PubMedPubMedCentralCrossRef
26.
Koerber K, Sass G, Kiemer AK, Vollmar AM, Tiegs G (2002) In vivo regulation of inducible NO synthase in immune-mediated liver injury in mice. Hepatology 36(5):1061–1069PubMedCrossRef
27.
Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Kunstle G et al (1997) In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 27(11):2870–2875PubMedCrossRef
28.
29.
Toyabe S, Seki S, Iiai T, Takeda K, Shirai K, Watanabe H et al (1997) Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 159(3):1537–1542PubMed
30.
Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G (1995) Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 21(1):190–198PubMed
31.
Kunstle G, Hentze H, Germann PG, Tiegs G, Meergans T, Wendel A (1999) Concanavalin A hepatotoxicity in mice: tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation. Hepatology 30(5):1241–1251PubMedCrossRef
32.
Streetz K, Fregien B, Plumpe J, Korber K, Kubicka S, Sass G et al (2001) Dissection of the intracellular pathways in hepatocytes suggests a role for Jun kinase and IFN regulatory factor-1 in Con A-induced liver failure. J Immunol 167(1):514–523PubMedCrossRef
33.
Liedtke C, Bangen JM, Freimuth J, Beraza N, Lambertz D, Cubero FJ et al (2011) Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 141(6):2176–2187PubMedCrossRef
34.
Maeda S, Chang L, Li Z-W, Luo J-L, Leffert H, Karin M (2003) IKKβ is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFα. Immunity 19(5):725–737PubMedCrossRef
35.
Seki E, Brenner DA, Karin M (2012) A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 143(2):307–320PubMedCrossRef
36.
Arshad MI, Rauch M, Ĺhelgoualćh A, Julia V, Leite-de-Moraes MC, Lucas-Clerc C et al (2011) NKT cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis. Eur J Immunol 41(8):2341–8PubMedCrossRef
37.
Neumann K, Karimi K, Meiners J, Voetlause R, Steinmann S, Dammermann W et al (2017) A proinflammatory role of type 2 innate lymphoid cells in murine immune-mediated hepatitis. J Immunol 198(1):128–137PubMedCrossRef
38.
Arshad MI, Piquet-Pellorce C, Filliol A, Ĺhelgoualćh A, Lucas-Clerc C, Jouan-Lanhouet S et al (2015) The chemical inhibitors of cellular death, PJ34 and Necrostatin-1, down-regulate IL-33 expression in liver. J Mol Med (Berl) 93(8):867–78CrossRef
39.
Douni E, Kollias G (1998) A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. J Exp Med 188(7):1343–1352PubMedPubMedCentralCrossRef
40.
Schumann J, Muhlen K, Kiemer AK, Vollmar AM, Tiegs G (2003) Parenchymal, but not leukocyte, TNF receptor 2 mediates T cell-dependent hepatitis in mice. J Immunol 170(4):2129–2137PubMedCrossRef
41.
Fotin-Mleczek M, Henkler F, Samel D, Reichwein M, Hausser A, Parmryd I et al (2002) Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci 115(Pt 13):2757–2770PubMedCrossRef
42.
Kubes P, Mehal WZ (2012) Sterile inflammation in the liver. Gastroenterol 143(5):1158–1172CrossRef
43.
Lee WM (2007) Acetaminophen toxicity: changing perceptions on a social/medical issue. Hepatol 46(4):966–970CrossRef
44.
Ramachandran A, McGill MR, Xie Y, Ni HM, Ding WX, Jaeschke H (2013) Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice. Hepatol 58(6):2099–2108CrossRef
45.
Jaeschke H, Williams CD, Ramachandran A, Bajt ML (2012) Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 32(1):8–20PubMedCrossRef
46.
Boess F, Bopst M, Althaus R, Polsky S, Cohen SD, Eugster HP et al (1998) Acetaminophen hepatotoxicity in tumor necrosis factor/lymphotoxin-alpha gene knockout mice. Hepatol 27(4):1021–1029CrossRef
47.
Chiu H, Gardner CR, Dambach DM, Durham SK, Brittingham JA, Laskin JD et al (2003) Role of tumor necrosis factor receptor 1 (p55) in hepatocyte proliferation during acetaminophen-induced toxicity in mice. Toxicol Appl Pharmacol 193(2):218–227PubMedCrossRef
48.
Gao B, Bataller R (2011) Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterol 141(5):1572–1585CrossRef
49.
Roychowdhury S, McMullen MR, Pisano SG, Liu X, Nagy LE (2013) Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatol 57(5):1773–1783CrossRef
50.
Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG (1997) Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatol 26(6):1530–1537CrossRef
51.
Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI et al (1999) Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterol 117(4):942–952CrossRef
52.
Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B et al (2008) A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterol 135(6):1953–1960CrossRef
53.
54.
55.
Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM et al (2017) NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol 66(5):1037–1046PubMedPubMedCentralCrossRef
56.
57.
Gomes AL, Teijeiro A, Buren S, Tummala KS, Yilmaz M, Waisman A et al (2016) Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30(1):161–175PubMedCrossRef
58.
59.
Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S et al (2018) The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatol 67(2):534–548CrossRef
60.
Glaser F, John C, Engel B, Hoh B, Weidemann S, Dieckhoff J et al (2019) Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. J Hepatol 71(4):783–792PubMedCrossRef
61.
Trauner M, Fuchs CD (2021) Novel therapeutic targets for cholestatic and fatty liver disease. Gut.
62.
Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389(6651):610–614PubMedCrossRef
63.
Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 100(11):2777–2782PubMedPubMedCentralCrossRef
64.
Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K et al (2006) Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26(1):39–45PubMedCrossRef
65.
Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C et al. (2021) Circulating tumor necrosis factor-alpha levels in non-alcoholic fatty liver disease: a systematic review and a meta-analysis. J Gastroenterol Hepatol.
66.
Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A et al (2001) Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatol 34(6):1158–1163CrossRef
67.
Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A et al (2006) Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55(3):415–424PubMedPubMedCentralCrossRef
68.
Wandrer F, Liebig S, Marhenke S, Vogel A, John K, Manns MP et al (2020) TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis 11(3):212PubMedPubMedCentralCrossRef
69.
Schramm C, Schneider A, Marx A, Lohse AW (2008) Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol 46(12):1369–1371PubMedCrossRef
70.
71.
Valaydon Z, Pellegrini M, Thompson A, Desmond P, Revill P, Ebert G (2016) The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunol 5(12):e115CrossRef
72.
Su F, Schneider RJ (1997) Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci U S A 94(16):8744–8749PubMedPubMedCentralCrossRef
73.
Jia B, Guo M, Li G, Yu D, Zhang X, Lan K et al (2015) Hepatitis B virus core protein sensitizes hepatocytes to tumor necrosis factor-induced apoptosis by suppression of the phosphorylation of mitogen-activated protein kinase kinase 7. J Virol 89(4):2041–2051PubMedCrossRef
74.
Puro R, Schneider RJ (2007) Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 81(14):7351–7362PubMedPubMedCentralCrossRef
75.
Biermer M, Puro R, Schneider RJ (2003) Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol 77(7):4033–4042PubMedPubMedCentralCrossRef
76.
Park YK, Park ES, Kim DH, Ahn SH, Park SH, Lee AR et al (2016) Cleaved c-FLIP mediates the antiviral effect of TNF-alpha against hepatitis B virus by dysregulating hepatocyte nuclear factors. J Hepatol 64(2):268–277PubMedCrossRef
77.
Park J, Kang W, Ryu SW, Kim WI, Chang DY, Lee DH et al (2012) Hepatitis C virus infection enhances TNFalpha-induced cell death via suppression of NF-kappaB. Hepatol 56(3):831–840CrossRef
78.
Xu H, Li H, Cao D, Wu Y, Chen Y (2014) Tumor necrosis factor alpha (TNF-alpha) receptor-I is required for TNF-alpha-mediated fulminant virus hepatitis caused by murine hepatitis virus strain-3 infection. Immunol Lett 158(1–2):25–32PubMedCrossRef
79.
Farooq M, Filliol A, Simoes Eugenio M, Piquet-Pellorce C, Dion S, Raguenes-Nicol C et al (2019) Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis. Cell Death Dis 10(1):12PubMedPubMedCentralCrossRef
80.
Lampl S, Janas MK, Donakonda S, Brugger M, Lohr K, Schneider A et al (2020) Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes. J Hepatol 73(6):1347–1359PubMedCrossRef
81.
Suresh M, Singh A, Fischer C (2005) Role of tumor necrosis factor receptors in regulating CD8 T-cell responses during acute lymphocytic choriomeningitis virus infection. J Virol 79(1):202–213PubMedPubMedCentralCrossRef
82.
Beyer M, Abdullah Z, Chemnitz JM, Maisel D, Sander J, Lehmann C et al (2016) Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. Nat Immunol 17(5):593–603PubMedCrossRef
83.
Ebert G, Preston S, Allison C, Cooney J, Toe JG, Stutz MD et al (2015) Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc Natl Acad Sci U S A 112(18):5797–5802PubMedPubMedCentralCrossRef
84.
Ebert G, Allison C, Preston S, Cooney J, Toe JG, Stutz MD et al (2015) Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci U S A 112(18):5803–5808PubMedPubMedCentralCrossRef
85.
Chyuan IT, Tsai HF, Tzeng HT, Sung CC, Wu CS, Chen PJ et al (2015) Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. Cell Mol Immunol 12(3):317–325PubMedPubMedCentralCrossRef
86.
de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ et al (2014) Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterol 147(2):443–52 e5CrossRef
87.
Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y et al (2021) An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. J Hepatol 75(3):572–581PubMedPubMedCentralCrossRef
88.
Gantner F, Leist M, Jilg S, Germann PG, Freudenberg MA, Tiegs G (1995) Tumor necrosis factor-induced hepatic DNA fragmentation as an early marker of T-cell-dependent liver-injury in mice. Gastroenterol 109(1):166–176CrossRef
89.
Schumann J, Angermuller S, Bang R, Lohoff M, Tiegs G (1998) Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J Immunol 161(10):5745–5754PubMed
90.
Dimopoulou D, Dimitroulas T, Akriviadis E, Garyfallos A (2015) Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis. Rheumatol Int 35(11):1913–1916PubMedCrossRef
91.
Bakula M, Mayer M, Cikes N, Anic B (2015) A patient with rheumatoid arthritis and primary biliary cirrhosis successfully treated with adalimumab. Lijec Vjesn 137(1–2):27–29PubMed
92.
Bovensiepen CS, Schakat M, Sebode M, Zenouzi R, Hartl J, Peiseler M et al (2019) TNF-producing Th1 cells are selectively expanded in liver infiltrates of patients with autoimmune hepatitis. J Immunol 203(12):3148–3156PubMedCrossRef
93.
Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT (1999) Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterol 117(3):645–652CrossRef
94.
Billmeier U, Dieterich W, Neurath MF, Atreya R (2016) Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 22(42):9300–9313PubMedPubMedCentralCrossRef
95.
LR Lopetuso, G Mocci, M Marzo, F D’aversa, GL Rapaccini, L Guidi et al. (2018) Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-alpha on the liver. Int J Mol Sci 19(8).
96.
Bjornsson HK, Gudbjornsson B, Bjornsson ES (2022) Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. J Hepatol 76(1):86–92PubMedCrossRef
97.
Kollias G, Kontoyiannis D, Douni E, Kassiotis G (2002) The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized ‘anti-TNF’ therapies. Curr Dir Autoimmun 5:30–50PubMedCrossRef
98.
99.
Tseng WY, Huang YS, Clanchy F, McNamee K, Perocheau D, Ogbechi J et al (2019) TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells. Proc Natl Acad Sci U S A 116(43):21666–21672PubMedPubMedCentralCrossRef
100.
Little R, Wine E, Kamath BM, Griffiths AM, Ricciuto A (2020) Gut microbiome in primary sclerosing cholangitis: A review. World J Gastroenterol 26(21):2768–2780PubMedPubMedCentralCrossRef
101.
Lazaridis KN, LaRusso NF (2016) Primary sclerosing cholangitis. N Engl J Med 375(25):2501–2502PubMed
102.
Schoknecht T, Schwinge D, Stein S, Weiler-Normann C, Sebode M, Mucha S et al (2017) CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood. J Leukoc Biol 101(2):589–597PubMedCrossRef
103.
Sebode M, Peiseler M, Franke B, Schwinge D, Schoknecht T, Wortmann F et al (2014) Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. J Hepatol 60(5):1010–1016PubMedCrossRef
104.
Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A et al (2007) Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 46(5):899–906PubMedCrossRef
105.
Ravichandran G, Neumann K, Berkhout LK, Weidemann S, Langeneckert AE, Schwinge D et al (2019) Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 71(4):773–782PubMedCrossRef
106.
Langeneckert AE, Lunemann S, Martrus G, Salzberger W, Hess LU, Ziegler AE et al (2019) CCL21-expression and accumulation of CCR7(+) NK cells in livers of patients with primary sclerosing cholangitis. Eur J Immunol 49(5):758–769PubMedCrossRef
107.
Kummen M, Thingholm LB, Ruhlemann MC, Holm K, Hansen SH, Moitinho-Silva L et al (2021) Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis. Gastroenterol 160(5):1784-98e0CrossRef
108.
Tedesco D, Thapa M, Chin CY, Ge Y, Gong M, Li J et al (2018) Alterations in intestinal microbiota lead to production of interleukin 17 by intrahepatic gammadelta T-cell receptor-positive cells and pathogenesis of cholestatic liver disease. Gastroenterol 154(8):2178–2193CrossRef
109.
Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T et al (2019) Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 4(3):492–503PubMedCrossRef
110.
Katt J, Schwinge D, Schoknecht T, Quaas A, Sobottka I, Burandt E et al (2013) Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatol 58(3):1084–1093CrossRef
111.
Stockinger B, Omenetti S (2017) The dichotomous nature of T helper 17 cells. Nat Rev Immunol 17(9):535–44PubMedCrossRef
112.
Poch T, Krause J, Casar C, Liwinski T, Glau L, Kaufmann M et al (2021) Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4(+) T cells in primary sclerosing cholangitis. J Hepatol 75(2):414–423PubMedPubMedCentralCrossRef
113.
Lynch KD, Keshav S, Chapman RW (2019) The use of biologics in patients with inflammatory bowel disease and primary sclerosing cholangitis. Curr Hepatol Rep 18(1):115–126PubMedPubMedCentralCrossRef
114.
Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A et al (2020) Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 18(10):2295–304 e2PubMedCrossRef
115.
Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H et al (2004) Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterol 127(1):261–274CrossRef
116.
Verhulst S, Best J, Syn WK, Reynaert H, Hellemans KH, Canbay A et al (2016) Infliximab and dexamethasone attenuate the ductular reaction in mice. Sci Rep 6:36586PubMedPubMedCentralCrossRef
117.
Berkhout L, Barikbin R, Schiller B, Ravichandran G, Krech T, Neumann K et al (2019) Deletion of tumour necrosis factor alpha receptor 1 elicits an increased TH17 immune response in the chronically inflamed liver. Sci Rep 9(1):4232PubMedPubMedCentralCrossRef
118.
Moriwaki K, Balaji S, Bertin J, Gough PJ, Chan FK (2017) Distinct kinase-independent role of RIPK3 in CD11c(+) mononuclear phagocytes in cytokine-induced tissue repair. Cell Rep 18(10):2441–2451PubMedPubMedCentralCrossRef
119.
Kempski J, Brockmann L, Gagliani N, Huber S (2017) TH17 cell and epithelial cell crosstalk during inflammatory bowel disease and carcinogenesis. Front Immunol 8:1373PubMedPubMedCentralCrossRef
120.
Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S et al (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446(7135):557–561PubMedCrossRef
121.
Ehlken H, Kondylis V, Heinrichsdorff J, Ochoa-Callejero L, Roskams T, Pasparakis M (2011) Hepatocyte IKK2 protects Mdr2-/- mice from chronic liver failure. PLoS One 6(10):e25942PubMedPubMedCentralCrossRef
122.
Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R et al (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11(2):119–132PubMedCrossRef
123.
Cubero FJ, Singh A, Borkham-Kamphorst E, Nevzorova YA, Al Masaoudi M, Haas U et al (2013) TNFR1 determines progression of chronic liver injury in the IKKgamma/Nemo genetic model. Cell Death Differ 20(11):1580–1592PubMedPubMedCentralCrossRef
124.
Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121(7):977–990PubMedCrossRef
125.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007):461–466PubMedCrossRef
126.
127.
Y Nie, J He, H Shirota, AL Trivett, Yang, DM Klinman et al (2018) Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. Sci Signal 11(511)
Metadata
Title
TNF in the liver: targeting a central player in inflammation
Authors
Gisa Tiegs
Andrea K. Horst
Publication date
04-02-2022
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 4/2022
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-022-00910-2

Other articles of this Issue 4/2022

Seminars in Immunopathology 4/2022 Go to the issue

Review

Th17 cells in the liver: balancing autoimmunity and pathogen defense

Review

B cells in autoimmune hepatitis: bystanders or central players?

Review

MAIT cells in liver inflammation and fibrosis

Review

Harnessing the liver to induce antigen-specific immune tolerance

Review

Bile acids and their receptors: modulators and therapeutic targets in liver inflammation

Review

The intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits